Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 233-786-0 | CAS number: 10361-29-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable publication which meets basic scientific principles.
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 002
Materials and methods
- Objective of study:
- metabolism
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Study of the effects of infusion of ammonium bicarbonate on glutamine metabolism in ovine splanchnic tissues.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Ammonium hydrogencarbonate
- EC Number:
- 213-911-5
- EC Name:
- Ammonium hydrogencarbonate
- Cas Number:
- 1066-33-7
- IUPAC Name:
- ammonium hydrogen carbonate
- Details on test material:
- Purity: no data
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- sheep
- Strain:
- other: Suffolk cross wether
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 39 +/- 3.1 kg
- Individual metabolism cages: yes
- Diet (e.g. ad libitum): 47 g grass pellets/0.75 kg bw/d as hourly portions
- Acclimation period: 3 weeks after surgery
- Other: prepared with vascular catheters in the aorta, mesenteric, portal and hepatic veins
Administration / exposure
- Route of administration:
- infusion
- Vehicle:
- water
- Details on exposure:
- TEST SCHEDULE
- For each animal, the experimental protocol involved 3 consecutive abomasal infusions of ammonium bicarbonate (23.4 μmol/kg, 365 μmol/min), an L-amino acid mixture at a rate of 730 μmol /min (46.8 μmol amino acid-N/kg) and water.
- L-glutamine solution (36 µM in sterile 0.15 M NaCl) was infused into the jugular catheter at a rate of 6 µmol/min the first 3 treatments.
On the fourth day the L-glutamine infusion was substituted by 100 ml 24 mM [5-15N]glutamine, which was infused at 6 µmol/min (15 g/h) for
6 h. - Duration and frequency of treatment / exposure:
- Each infusion was for 4 days at a rate of 60 g/h, allowing at least 10 days between the ammonium bicarbonate and amino acid-N infusions.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
- ammonium bicarbonate at a rate of 23.4 μmol/kg: 365 μmol/min
- L-amino acid mixture at a rate of 730 μmol /min: 46.8 μmol amino acid-N/kg
- No. of animals per sex per dose / concentration:
- Three animals were infused in the order: ammonium bicarbonate, water and amino acid while the other 3 received the reverse sequence.
- Control animals:
- yes
- Details on study design:
- Three animals were infused in the order AMM, CONT, AA while the other three received the reverse sequence (AA, CONT, AMM). Each infusion was for 4 d at a rate of 60 g/h, allowing at least 10 d between the AMM and AA treatments. The CONT infusion was allocated in the middle of the other two treatments to allow maximum time spacing between AA and AMM infusion, and was started at least 3 d after finishing the previous treatment.
- Details on dosing and sampling:
- PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: blood, plasma
- Time and frequency of sampling: Over 1 h intervals, between 2 and 6 h after [5- 15N]glutamine infusion
Results and discussion
Metabolite characterisation studies
- Metabolites identified:
- not measured
Any other information on results incl. tables
- Blood flow across the whole gut or liver were unaffected by treatment.
- Both ammonium bicarbonate and amino acid-N infusions doubled the hepatic release of urea-N compared with water treatment.
- Ammonium acid infusion decreased arterial glutamine concentration by 26% and 23% compared with ammonium bicarbonate and water respectively. Despite this, whole-body glutamine flux was not affected by treatment. In contrast, ammonium bicarbonate infusion increased hepatic production by 40% compared with water. This provided a mechanism to ensure NH3 supply to the periphery was maintained within the normal low physiological levels. Hepatic glutamine utilisation tended to increase during amino acid infusion, probably to ensure equal inflows of N to the ornithine cycle. When NH3 supply exceeds the capacity of the ornithine cycle (periportal) then it is used as a substrate for glutamine synthesis (perivenous). Therefore, excess NH3 supply may lead to an increase in glutamine synthesis, while amino acid excess may increase hepatic glutamine use.
- Between 6 and 10% of NH3 absorbed across the digestive tract was derived from the amido-N of glutamine. Overall, splanchnic glutamine utilisation accounted for 45-70% of whole-body glutamine flux
Effects on on plasma ammonia and blood water urea concentration:
*p<0.005
Ammonium bicarbonate | Water | Amino acids | ||
NH3 concentration (µM) | Arterial | 87 | 87 | 130 |
Portal | 489* | 269 | 356* | |
Hepatic | 74 | 42 | 51 | |
urea concentration (µM) | Arterial | 8.61* | 4.41 | 8.44* |
Portal | 8.42* | 4.31 | 8.32* | |
Hepatic | 8.81* | 4.48 | 8.62* |
Applicant's summary and conclusion
- Conclusions:
- In conclusion, splanchnic glutamine utilisation was shown to account for the majority of whole-body plasma glutamine flux, under conditions which simulated nutritional extremes in ruminant animals.
- Executive summary:
This study investigates the effects of increased NH3 or amino acid supply on glutamine utilisation and production by the splanchnic tissues of fed sheep.
In conclusion, splanchnic glutamine utilisation was shown to account for the majority of whole-body plasma glutamine flux, under conditions which simulated nutritional extremes in ruminant animals. The PDV tissues had a lower demand for glutamine when amino acids were infused, indicative of sparing by other metabolites. Hepatic glutamine utilisation increased during both NH3 and amino acid infusion, while production increased by 40 %, compared with basal conditions, when ammonium bicarbonate was infused. This provided an effective strategy to prevent peripheral hyperammonaemia. Peripheral glutamine production contributed to the balance of
whole-body glutamine metabolism and varied with the form of nutrient supply.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.